Literature DB >> 8001009

Leukemias, myeloma, and other lymphoreticular neoplasms.

J A Hernández1, K J Land, R W McKenna.   

Abstract

BACKGROUND: The purpose of this study was to assess the occurrence of various morphologic types of leukemia and myeloma within patient demographic groups and to correlate findings with data-reporting periods and other variables, such as 5-year relative survival.
METHODS: Data from 31,850 cases of multiple subgroups of acute and chronic leukemia, 12,237 cases of myeloma, and 321 cases of "other" lymphoreticular neoplasms were collected by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. The data were examined by age, sex, race, age-specific and age-adjusted incidence rate, and patient 5-year relative survival during three reporting periods: 1973-1977, 1978-1982, and 1983-1987.
RESULTS: The age-adjusted incidence rate for all categories of leukemia combined has been constant, but there has been an increase in the relative frequency (percentage) of acute lymphoid leukemia (ALL) in the general population and a rising incidence rate of myeloid leukemia in the black population. The increase of ALL is offset by a decline of acute myeloid leukemias (AMLs) and acute leukemia, not otherwise specified. The age-adjusted rate of ALL in whites, 1.5 per 100,000 per year, is twice that of blacks, 0.8. The rates for each of the major categories of leukemia are considerably higher in males than in females. Five-year survival rates changed very little for leukemias over the 15 years of the study except for ALL, in which there was a marked improvement between the first (1973-1977) (39.1%) and second (1978-1982) (51.3%) reporting period. The SEER data confirm that multiple myeloma is predominantly a disease of late adulthood and occurs more frequently in blacks and males. The incidence rate of multiple myeloma has not changed during the 15 years surveyed. The 5-year relative survival rate has remained nearly constant for multiple myeloma. There is a marked difference in 5-year relative survival rates for patients with plasmacytoma of bone marrow (45.7%), multiple myeloma (25.9%), and plasma cell leukemia (13.0%).
CONCLUSIONS: Shifts in the relative frequencies of leukemia types may have been affected by changes in classification criteria, changes in the use of histologic terms over time, and the expanded use of immunophenotyping and other technology to characterize acute leukemias. Incidence rates and 5-year relative survival rates for myeloma have remained stable.

Entities:  

Mesh:

Year:  1995        PMID: 8001009     DOI: 10.1002/1097-0142(19950101)75:1+<381::aid-cncr2820751320>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  A Case of Multiple Myeloma: Mimicking Carcinoma Larynx.

Authors:  Santhosh Kumar Nochikattil; Elizabeth Mathew Iype; Surnare Kailash Ramrao; Preethi Nair; Shaji Thomas
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2016-05-10

Review 2.  Dielectrophoresis-based microfluidic platforms for cancer diagnostics.

Authors:  Jun Yuan Chan; Aminuddin Bin Ahmad Kayani; Mohd Anuar Md Ali; Chee Kuang Kok; Burhanuddin Yeop Majlis; Susan Ling Ling Hoe; Marini Marzuki; Alan Soo-Beng Khoo; Kostya Ken Ostrikov; Md Ataur Rahman; Sharath Sriram
Journal:  Biomicrofluidics       Date:  2018-02-23       Impact factor: 2.800

3.  Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen.

Authors:  Christoph Steininger; George F Widhopf; Emanuela M Ghia; Christopher S Morello; Katrina Vanura; Rebecca Sanders; Deborah Spector; Don Guiney; Ulrich Jäger; Thomas J Kipps
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

Review 4.  Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.

Authors:  Hima V Vangapandu; Nitin Jain; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2017-04-13       Impact factor: 6.206

5.  Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia.

Authors:  C Steininger; L Z Rassenti; K Vanura; K Eigenberger; U Jäger; T J Kipps; C Mannhalter; S Stilgenbauer; T Popow-Kraupp
Journal:  Eur J Clin Invest       Date:  2009-06       Impact factor: 4.686

6.  Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.

Authors:  Rabih Said; Apostolia M Tsimberidou
Journal:  Expert Opin Biol Ther       Date:  2017-09-11       Impact factor: 4.388

7.  Evaluation of seasonality in the diagnosis of acute myeloid leukaemia among adults in the United States, 1992-2008.

Authors:  Gregory S Calip; Jean A McDougall; Mark C Wheldon; Christopher I Li; Anneclaire J De Roos
Journal:  Br J Haematol       Date:  2012-11-28       Impact factor: 6.998

Review 8.  Novel agents for chronic lymphocytic leukemia.

Authors:  Mei Wu; Akintunde Akinleye; Xiongpeng Zhu
Journal:  J Hematol Oncol       Date:  2013-05-16       Impact factor: 17.388

9.  A case of chronic lymphocytic leukemia with massive ascites.

Authors:  Ipek Yonal; Esra Nazlıgul; Gulsum Tas; Mehmet Ramazan Agan; Mustafa Nuri Yenerel; Meliha Nalcaci
Journal:  Rare Tumors       Date:  2012-11-13

10.  Cancer incidence among adolescents and young adults in urban Shanghai, 1973-2005.

Authors:  Qi-Jun Wu; Emily Vogtmann; Wei Zhang; Li Xie; Wan-Shui Yang; Yu-Ting Tan; Jing Gao; Yong-Bing Xiang
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.